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ABSTRACT 
 
Globally, there is an increasing prevalence of non-communicable diseases.  The morbidity and mortality from 
these conditions confer a greater economic societal burden.  Epidemiological research associates insulin 
resistance in the etiology of these diseases, but there is limited evidence for the mechanism of damage.  
Emerging research suggests that hyperinsulinemia, a symptom of insulin resistance, may cause these 
pathological changes, and therefore be an independent contributor to these diseases.  This review shows that 
hyperinsulinemia, or excessive insulin secretion, should be considered independently to insulin resistance, defined 
as glucose uptake rate, even though the two conditions are intertwined and will co-exist under normal 
conditions. Hyperinsulinemia directly and indirectly contributes to a vast array of metabolic diseases including all 
inflammatory conditions, all vascular diseases, gestational and type 2 diabetes, non-alcoholic fatty liver disease, 
obesity and certain cancers and dementias. The mechanisms include increased production of: insulin growth 
factor-1; reactive oxidative species and advanced glycation end-products; and triglyceride and fatty acids.  
Hyperinsulinemia also directly and indirectly affects many other hormones and cytokine mechanisms including 
leptin, adiponectin and estrogen. There is limited research standardizing the hyperinsulinemia diagnostic process.  
Methodological concerns and lack of standardized reference ranges preclude the use of fasting insulin.  Most 
research has also focused on insulin resistance and it is unknown whether these methods translate to 
hyperinsulinemia. 
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Introduction 
Impaired insulin homeostasis encompasses 
both hyperinsulinemia and hypoinsulinemia. Although 
the latter is well recognised as type 1 diabetes, there is 
little literature on the former, despite being first 
hypothesised in the early 1920s.1 Currently, a close 
approximation to hyperinsulinemia research is that 
conducted on insulin resistance. Insulin resistance is 
well-established as underpinning many significant 
chronic health conditions including type 2 diabetes, 
metabolic syndrome, cardiovascular disease, some 
cancers and Alzheimer’s disease.2-5 This insulin 
resistance is invariably accompanied by increased 
demands for insulin so that the body can maintain 
euglycemia. Excess insulin, termed hyperinsulinemia, 
may be endogenous from bodily compensation, or 
exogenous via modern medicine. In this paper we 
contend that hyperinsulinemia, in concert with insulin 
resistance, should be considered as an important 
independent health risk. We exclude isolated 
hyperinsulinemia, such as that caused by an 
insulinoma. 
 
 
 
It is well recognised that earliest detection of 
any disease state allows for the best possible 
outcomes. It is agreed that hyperinsulinemia precedes 
hyperglycemia, by up to 24 years.3, 4, 6 There is a strong 
argument that hyperglycemia indicates pancreatic β-
cell attrition; essentially end-stage organ damage.3, 7 We 
contend that the under-recognition of 
hyperinsulinemia is an important clinical issue because 
there are no standard diagnostic reference values, is 
most accurately diagnosed with dynamic glucose and 
insulin testing, and has few (pharmaceutical) 
management options. This review will discuss 
pathophysiology and diagnosis of hyperinsulinemia.   
Hyperinsulinemia was first theorised in 19241, 
but it was not until the 1960’s that direct insulin 
measurements became possible.8 Since then, there has 
been a wealth of research in the field of insulin 
resistance with a small amount of research into 
hyperinsulinemia. Therefore, we highlight the disease 
states that are both directly and/or indirectly 
associated with hyperinsulinemia. We also discuss the 
availability and limitations of current diagnostic 
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methods for hyperinsulinemia and why further 
investigations are needed. 
 
Methodology 
For this narrative review, literature was reviewed on 
hyperinsulinemia and insulin resistance, targeting full-
text English language studies. There was no date 
criterion. Articles were selected on the basis of having 
a minimum of both a plausible biological mechanism 
and established clinical association.  Initially, the  
academic database search included EBSCO, Medline 
and Google Scholar, using variants of the terms 
‘hyperinsulinemia’, ‘insulin resistance’, ‘metabolic 
syndrome’, and ‘syndrome x’, individually and 
conjunction with ‘non-communicable disease’, 
‘mechanism’, ‘atherosclerosis’, and ‘cardiovascular 
disease’. As subsequent metabolic diseases and/or 
mechanisms were eluded to in the initial search, search 
terms were widened so that no disease state was 
excluded. Subsequent metabolic diseases included, but 
were not limited to, conditions such as ‘non-alcoholic 
fatty liver disease’, ‘cancer’, ‘dementia’. The final 
selection of references was based on the authors’ 
judgment of relevance, completeness, and 
compatibility with clinical, epidemiological, 
pathological and biochemical criteria. 
 
Hyperinsulinemia 
 
Definition 
There is no precise definition of 
hyperinsulinemia. It is often described as ‘more insulin 
than normal to achieve euglycemia’; essentially the 
same as insulin resistance.  Where a reference range is 
available, it is normally based on fasting levels and 
include 5-13 µU/mL9, ≤ 30 µU/mL10, and 18-173 
pmol/L (3-28 µU/mL)11 However, there are very few 
studies where a ‘normal level of insulin’ is defined as 
many studies define hyperinsulinemia based on 
quantiles.12-14 Few studies have been more specific. 
Both a fasting serum insulin of ≥12.2 µU/mL in the 
presence of euglycemia15 and a range of 8-11 µU/mL 
‘between meals’ and up to 60 µU/mL ‘after meals’16 
have been proposed.  There are also practical, 
methodological issues with determining insulin 
resistance under the World Health Organization 
(WHO) conditions that will be discussed later in this 
review. 
 
Etiology 
The etiology of hyperinsulinemia is not yet 
fully elucidated. Although there are several theories, 
further research will likely show a multimodal 
pathology. What can be deduced from physiological 
principles is: 
1. Healthy cells are subjected to acute hyperglycemia.       
2. Although many cells can absorb glucose without 
using insulin (GLUT1 transportation) hyperglycemia 
causes insulin to be released from pancreatic cells to 
facilitate absorption, especially in muscle and adipose 
cells (GLUT 4 transportation).17 3. Insulin binds to 
cellular insulin receptors and facilitates translocation of 
GLUT4 to the cellular surface. During this process the 
insulin and its receptor are absorbed into the cell to be 
replaced from the internal pool of insulin receptors.18 
4. This acute insulin resistance is of no consequence as 
long as the cell has viable GLUT4 on the cellular 
surface. However, GLUT4 have a relatively short half-
life.19 5. If hyperglycemia persists, the pancreas 
maintains insulin secretion. This may deplete the 
insulin receptors faster than they can be replaced. 6. 
During this period where the cells are replacing their 
insulin receptors, moderately elevated blood glucose 
levels, (such as that immediately found after a normal 
meal) may need slightly higher than normal insulin 
levels to restore normoglycemia. This moderate 
hyperinsulinemia may delay the return to normal 
insulin receptor function (acute insulin resistance).7 
This state of insulin resistance due to down-regulated 
insulin receptors is reversible should the person not be 
subjected to further episodes of hyperglycemia. It does 
not matter whether this is via high, but acute, blood 
glucose elevations, or moderately elevated glucose 
levels over a prolonged period. 8. Prolonged impaired 
insulin signaling impedes GLUT4 translocation to the 
cellular surface thus causing impaired glucose uptake 
and prolonging hyperglycemia, causing a positive 
feedback cycle. This will both aggravate and prolong 
the insulin resistance, potentially turning it from a 
transitory state to a persistent or chronic state. 
The complexity of the insulin receptor 
regulation, combined with the availability of GLUT4 
and factors that influence insulin secretion mean that 
it is impossible to generalize whether insulin resistance 
precedes or follows hyperinsulinemia.  It is more 
plausible that different individuals have different 
triggers in the cycle.  These triggers may include 
genetic factors, excessive carbohydrate, corticosteroids 
(endogenous or exogenous), free fatty acids, leptin, or 
certain medications; each of these are discussed below. 
 
Fructose: Fructose is metabolized in liver into ATP 
and/or triglycerides in a process that is competitive 
with, and preferential to, glucose.  If excessive fructose 
is consumed, glucose will not be metabolized causing 
hyperglycemia and subsequent hyperinsulinemia.20, 21 
Excessive fructose also results in hyperuricemia which 
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is associated with reduced endothelial nitric oxide 
causing vasoconstriction, endothelial dysfunction and 
insulin resistance.21 
Hyperglycemia: Hyperglycemia alone can aggravate 
insulin resistance.22 Along with excessive carbohydrate 
ingestion, other mechanisms for this mechanism 
include hepatic insulin resistance. Increased plasma 
insulin slows hepatic gluconeogenesis but this process 
can be impaired by hepatic insulin resistance leading to 
peripheral hyperglycemia and further insulin 
secretion.23   
Corticosteroids: It is known that corticosteroids, 
especially endogenous cortisol, cause a down 
regulation of GLUT-4 receptors, thus preventing 
glucose uptake and provoking hyperinsulinemia in the 
presence of hyperglycemia. Long-term courses of 
exogenous corticosteroids, such as prednisone, are 
known to cause ‘drug-induced’ type 2 diabetes, which 
may resolve after the medication is discontinued. Not 
every patient on long-term corticosteroids will develop 
drug-induced diabetes. Therefore, it is plausible that 
the patient’s degree of insulin resistance at baseline 
influences disease development/progression. Given 
that stress causes a temporary rise in cortisol levels, it 
is also plausible that prolonged stress may be another 
cause of hyperinsulinemia.24  
Leptin: Appetite control is mediated from the 
hypothalamus in response to a balance between leptin 
and insulin controlling neuropeptide Y expression.25 
This balance is believed important to manage caloric 
intake over longer periods of time when meals can 
vary in size, frequency and composition. Leptin 
secretion is slow to change as it is influenced by total 
body fat mass and total caloric intake, while insulin 
secretion is highly responsive to food ingestion and 
will change quickly with every meal. Leptin is also 
highly influenced by insulin as it is released from fat 
stores by mechanisms that appear to involve glucose 
flux.25 Experimental evidence shows that reducing 
insulin secretion reduces leptin resistance, suggesting a 
relationship between hyperinsulinemia and 
hyperleptinemia.26 It is not yet clear whether 
hyperleptinemia is causative of hyperinsulinemia 
beyond the association of obesity and an increase in 
free fatty acids. 
Medication-induced: There are a number of medications 
known or suspected to cause hyperinsulinemia and/or 
contribute to insulin resistance. Exogenous 
corticosteroids (prednisone) and exogenous insulin 
and insulin secretagogues (sulphonylureas) have had 
their mechanisms discussed.  Other medications 
include the antipsychotics (e.g. clozapine), and 
statins.27 The mechanisms for these medications 
causing hyperinsulinemia are currently unknown. 
Due to the nature of insulin receptor 
regulation, it is also plausible that insulin sensitivity of 
the cells can be restored. This would require the 
absence of both hyperinsulinemia and hyperglycemia. 
Case studies indicate that a carbohydrate restricted diet 
may facilitate this effect.10 
Overall, it should be recognized that 
hyperinsulinemia is independent to insulin resistance: 
Hyperinsulinemia is excessive insulin secretion, while 
insulin resistance is impaired glucose uptake.  This 
review investigates the both the mechanistic and 
epidemiological evidence that links hyperinsulinemia 
to metabolic disease. Although there is good quality 
research mechanistically linking hyperinsulinemia to 
subsequent pathologies, there is a paucity of good 
epidemiological evidence. Given the intertwined 
nature between insulin resistance and hyperinsulinemia 
as depicted above, it can be assumed that the majority 
of people with insulin resistance are also 
hyperinsulinemic. Therefore, if no epidemiological 
data was available, this review used epidemiological 
research based on insulin resistance as a proxy for 
hyperinsulinemia. 
 
Direct effects of hyperinsulinemia 
As shown in Table 1, hyperinsulinemia can be 
mechanistically and epidemiologically linked to 
metabolic syndrome, gestational and type 2 diabetes 
and therefore, cardiovascular and other diseases with 
an increased prevalence in those with metabolic 
syndrome.2-4, 28  It is also an independent risk factor for 
a number of other diverse conditions including diet-
induced obesity, osteoarthritis, certain cancers, 
especially breast and colon/rectum, and Alzheimer’s 
disease and other dementias.5, 6, 29-32   
Other conditions that may be associated with 
hyperinsulinemia, via either epidemiological evidence 
or potential mechanism of action, include gout, 
tinnitus, schizophrenia and autism.33-36 Further 
research is needed to confirm these associations. 
 
Pathophysiological mechanisms 
Hyperinsulinemia affects the body via five 
main mechanisms: Increased reactive oxidative species 
and advanced glycation end-products; increased 
insulin-like growth factor-1 (IGF-1); hyperglycemia; 
increased fatty acid/triglyceride production; and by 
affecting different hormones and cytokines. 
 
Reactive oxidative species 
Reactive oxygen species is a collective term that 
includes both oxygen radicals and non-radical  
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Table 1. Biological systems and disease states affected by hyperinsulinemia, and associated mechanisms of action
Biological 
System 
Disease Mechanism 
Direct or 
indirect 
mechanism 
References 
Mechanism 
of action 
Epidemiology 
Cancer* 
Cancer           
(Breast, ovarian, colon, 
bladder, pancreas & 
liver) 
Increased insulin-like growth factor IGF-1 enhances cellular 
growth and proliferation. 
Direct (5, 48) (29) 
 Enhanced glucose uptake and utilization enhances cellular 
growth and proliferation. 
Both (29) (29) 
Increased production of reactive oxidative species causes 
derangement of DNA and enzymes involved with repair 
mechanisms (enhanced by hyperglycemia). 
Indirect (2, 37, 38) (2, 37, 38) 
Increased sex-hormone production and decreased sex 
hormone binding globulin causes increased cellular growth 
and proliferation (enhanced by obesity). 
Direct (29) (29) 
Circulatory 
 
Atherosclerosis 
Arterial wall damage caused by inflammation, increased 
proliferation and migration of arterial smooth muscle cells.  
Stimulation of the mitogen-activated protein kinase pathway. 
Both (28, 40) 
(28, 47, 63, 
64) 
Cardiomyopathy 
Microvascular disease, including changes to capillary 
permeability, microaneurysm formation, vasoconstriction and 
microthrombi. 
Both (65, 66) (65, 66) Increased myocardial fibrosis by increased reactive 
oxidative species, deranged collagen production. 
Diabetic neuropathy causes changes to catecholamines, which 
further impairs myocardial function. 
Endothelial dysfunction 
 
Vasoconstriction and pro-atherosclerotic effects from 
decreased nitric oxide bioavailability and action and 
increased thromboxane.   
Both (2, 41, 67) (64) 
Enhanced by increased reactive oxidative species and 
advanced glycation end-products. 
Thrombosis 
Hyperinsulinemia causes increased fibrinolysis while 
hyperglycemia causes increased blood coagulability 
. 
Indirect (42) (64) 
Gastrointestinal 
Diabetes: Gestational 
Pre-existing insulin resistance and increased demand for 
insulin. 
Direct (68) (68) 
Diabetes:   
Type 2 
Prolonged insulin resistance eventuating in beta-cell failure.  
Down-regulation of glucose transporter-4.   
Direct (3, 69, 70) (4) 
Hyper- triglyceridemia Increased triglyceride production.  Direct (43, 71) (72) 
Non-alcoholic fatty 
liver disease 
Fatty acid production exceeds distribution capacity.  
Aggravated by inflammation and oxidative stress. 
Direct (71) (72) 
Endocrine Chronic inflammation 
Stimulation of mitogen-activated protein kinase pathway; 
glycemic variability; hyperglycemia and/or obesity 
influences increased cytokine production. 
Indirect (40, 48) (73) 
 Obesity Decreased lipolysis. Direct (74) (75) 
  Lack of appetite suppression.   Direct (25, 26) (76) 
Nervous 
Alzheimer's disease 
and vascular dementia 
Endothelial dysfunction resulting in microvascular disease, 
metabolic disturbances and neuronal damage. 
Direct (2, 67, 77) (30, 78, 79) 
  
Increased blood coagulability and/or fibrinolysis cause 
multiple thrombotic events. 
Both (42, 80)  
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Changed regulation of beta-amyloid and tau protein 
(Alzheimer's disease). Direct (77, 81)  
  
Decreased synaptic plasticity caused by dysregulated PSA-
NCAM interactions (Alzheimer's disease). 
Direct (33)  
 Peripheral neuropathy 
Increased production of reactive oxidative species and 
advanced glycation end-products enhanced by 
hyperglycemia.  
Indirect (2, 41) (64, 82) 
  Insulin resistance in the dorsal root ganglion neurons.  Both (83)  
 Retinopathy 
Hyperglycemia and endothelial dysfunction contribute blood-
retinal barrier breakdown. Aggravated by excess advanced 
glycation end-products.   
Direct (41, 64, 84) (41, 64, 84) 
Skeletal Osteoporosis 
Increased reactive oxidative species and/hyperglycemia 
cause collagen breakdown, impairs new collagen synthesis 
and compromises mensenchymal cells. 
Indirect (31) (31) 
Urinary Nephropathy 
Microvascular disease, including changes to capillary 
permeability, microaneurysm formation, vasoconstriction and 
microthrombi. 
Direct (67, 85) (64, 86) 
  
Increased production of reactive oxidative species and 
advanced glycation end-products enhanced by 
hyperglycemia.  
Indirect (41, 87)  
*While cancer is not typically classified as a “biological system”, due to its recognition and impact as a key chronic disease, it was decided that it warrants a 
classification on its own, rather than be integrated into individual biological systems. PSA-NCAM-polysialic acid - neural cell adhesion molecule. 
oxidising agents such as hydrogen peroxide.37 Reactive 
oxidative species are also produced during, and 
involved in, many metabolic processes including 
enzymatic reactions, gene expression and signal 
transduction.37 Generally, the actions of intracellular 
reducing agents such as antioxidants prevent reactive 
oxidative species-mediated damage. However, a 
number of factors can contribute to excessive 
production of reactive oxidative species including 
excessive calorie consumption and the presence of 
various pro-inflammatory mediators, including tumor 
necrosis factor-α.37 Once produced, reactive oxidative 
species can interact with numerous cellular 
components including DNA, lipids, and amino acids.  
Damage to DNA is likely to be the underlying 
mechanism for reactive oxidative species being 
associated with cancer and early aging.38 
Polyunsaturated fatty acids are considered very 
susceptible to reactive oxidative species damage, 
triggering lipid peroxidation, which can affect cell 
membrane fluidity and integrity, potentially being the 
mechanism for endothelial damage.37 Amino acids 
such as cysteine and methionine are very susceptible to 
reactive oxidative species damage.  Changes to these 
amino acids are implicated in the development of 
Alzheimer’s disease.39 
Hyperinsulinemia is associated with increased 
reactive oxidative species, although the exact 
mechanism is disputed. Hyperinsulinemia is 
mechanistically linked to excessive serum glucose and 
free fatty acids. Either substrate can cause increased 
reactive oxidative species production.2 Insulin has also 
been demonstrated to have some inhibitory effects on 
reactive oxidative species production that may be 
independent of its effects on glycemia.40 However, 
reducing insulin-stimulated nutrient uptake into the 
cell is also believed to decrease reactive oxidative 
species production.2 Further research is required to 
better understand these mechanisms. 
Over-nutrition is also thought to be 
responsible for the formation of advanced glycation 
end-products via non-enzymatic glycation and 
glycooxidation processes.41 Defective renal excretion 
of advanced glycation end-products, as seen with 
diabetic nephropathy, and consumption of exogenous 
advanced glycation end-products increases plasma 
advanced glycation end-product levels. Advanced 
glycation end-products are believed to contribute to 
changes in the microvascular systems and also 
promote changes to inflammatory, oxidative and other 
degenerative processes of various chronic diseases 
including neuropathies.41 
 
Growth factors (IGF, vascular endothelial growth 
factor) 
Insulin, IGF-1 and other substances such as 
vascular endothelial growth factor (VEGF) can 
stimulate the growth and division of many cells. 
Insulin can mediate cellular division but may also 
stimulate cancer cell proliferation and metastasis.29 
Most importantly, insulin increases the bioavailability 
of IGF-1, thus insulin is indirectly implicated in all 
IGF-1 mediated processes.  These processes include 
changes to vascular structures, increases to cellular 
division and prevention of apoptosis 
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Hyperglycemia 
Hyperglycemia commonly follows 
hyperinsulinemia3 but there is little information to 
suggest whether fasting glucose, peak glucose, or area-
under-the curve (AUC) have the most adverse health 
impact. Cancer cells have a continuously high glucose 
uptake, which enhances cellular growth and 
proliferation29; hyperglycemia augments this process. 
Hyperglycemia allows IGF-1 to stimulate vascular 
smooth muscle proliferation, which is a hall-mark of 
both cancer and atherosclerosis. Blood coagulability is 
also increased by hyperglycemia irrespective of insulin 
levels.42 
 
Increased fatty acid and triglyceride production 
Hyperinsulinemia influences both free fatty 
acid and triglyceride production.43  While the processes 
that occur during hepatic de novo lipogenesis are not 
disputed, there is debate as to whether 
hyperinsulinemia precedes, or are a consequence of 
fatty liver.44 Nevertheless, elevated triglyceride levels 
are recognized to be a key component of metabolic 
syndrome (Table 1) while fatty liver may be considered 
a hepatic manifestation of metabolic syndrome and 
may progress to cirrhosis or hepatocellular cancer.44 
Elevated triglyceride levels may also further impair 
leptin resistance.20, 45 
   
Hormone/cytokine production (sex hormones, 
inflammation, obesity) 
Hyperinsulinemia is involved with adiposity 
via increased appetite and triglyceride production, 
thereby increasing adiposity.46, 47 Adipose tissue is now 
well-established as an endocrine organ and produces 
both hormones and cytokines that are used for cellular 
communication. Hypertrophic adipose tissues activate 
inflammatory and stress pathways and decreases 
insulin response. This results in increased cytokine 
production including TNF-α, vascular endothelial 
growth factor and leptin, while adiponectin expression 
is decreased.48 These actions contribute to decreased 
glucose and lipid uptake, leading to further reductions 
to adiponectin secretion and adipogenesis as well as 
contributing to further insulin resistance. Decreased 
glucose uptake means there is less glycerol within the 
adipocyte to esterify free fatty acids, allowing them to 
infiltrate and accumulate in other tissues. 
Adiponectin decreases proliferation of cell 
types including adipocytes, endothelial cells and cancer 
cells.48 The role of leptin is yet to be fully understood, 
but it is accepted that hyperinsulinemia and 
hyperleptinemia results in central leptin resistance, and 
consequent prevention of appetite suppression and 
promotion of further obesity.25, 26, 49 Hyperleptinemia 
is also linked to increased inflammatory cytokines, 
changes in nitric oxide, and further endothelial 
injury.49 
Hyperinsulinemia is also believed to elevate 
plasminogen activator inhibitor type-1 (PAL-1) levels, 
with associated increased fibrinolysis and increased 
risk of thrombosis. When combined with the 
increased coagulation from hyperglycemia, this may 
explain why over 80% of people with type 2 diabetes 
have a thrombotic death.42 
 
Diagnosis 
Diagnosing hyperinsulinemia is challenging 
partly because the health effects of insulin resistance 
and hyperinsulinemia have been conflated. Further 
challenges arise when interpreting the available 
literature.  As previously discussed, fasting insulin 
levels have been assessed as a means of diagnosing 
hyperinsulinemia with differing results. But it is not 
just the insulin level alone that is problematic. How 
and when sampling occurs will also cause variation to 
results. Insulin levels are higher in serum compared to 
plasma samples meaning that studies reporting serum 
insulin cannot be compared directly to plasma 
insulin.50, 51 Insulin secretion is pulsatile leading to 
significant levels in plasma insulin in a short space of 
time. It is recommended that the mean of three 
samples taken at five minute intervals be used if a 
fasting insulin level is required52, however this rarely 
seem to happen in practice.  Single fasting insulin 
samples can have a coefficient of variation of 25-
50%.53 This variation decreases testing sensitivity and 
is perhaps why fasting insulin is not recommended to 
be used clinically.54 
It is unknown whether insulin resistance 
testing can be used to diagnose hyperinsulinemia.  The 
gold standard for measuring insulin resistance is the 
hyperinsulinemic-euglycemic clamp test. The lowest 
quartile of glucose uptake rate defines insulin 
resistance for that study population. Figures for this 
lower quartile have ranged from < 4.7mg/kg ·min to 
≤ 6.3M·mU-1·L-1, however differences in insulin 
infusion rates, glucose disposal rate calculations, and 
background populations under investigation means 
that there are limits to the generalizability of these 
results.15, 55-58 Furthermore, given the complexity of the 
procedure, the  hyperinsulinemic-euglycemic clamp 
test has little to no clinical application.15 
A further complication to using the clamp test 
to assess hyperinsulinemia is that the high dose 
infusion of insulin will confound any effects of 
endogenous insulin secretion.  As theorized above, the 
damage associated with hyperinsulinemia is due to the 
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continuous action of insulin in the tissues. The 
amount of insulin normally present in the tissues 
cannot be measured during the clamp process. It is 
unknown whether glucose uptake rates correlate with 
insulin secretion. 
A number of tests have been developed that 
are validated against the hyperinsulinemic-euglycemic 
clamp that has more clinical applicability.  Those based 
on fasting insulin include homeostatic model 
assessment (HOMA or HOMA2), McAuley Index, 
and the quantitative insulin sensitivity check index 
(QUICKI).15, 56, 59 Although HOMA has since been 
refined to the HOMA2 model, both are modelled on 
the combination of fasting insulin to fasting glucose.  
The original HOMA has a 89% sensitivity and 67% 
specificity compared to hyperinsulinemia-euglycemic 
clamp.57 The McAuley index is calculated from fasting 
insulin and fasting triglyceride levels with 61% 
sensitivity and 85% specificity.15 
Another insulin resistance test, the oral 
glucose sensitivity index (OGIS), is modelled on the 
results derived from an oral glucose tolerance test.56  
OGIS uses both blood insulin and glucose levels at 
baseline, 120 min and 180 min.  A spreadsheet is 
recommended for the calculations (available from 
http://webmet.pd.cnr.it/ogis/download.php).  The 
OGIS is validated against the hyperinsulinemic-
euglycemic clamp assessments for insulin resistance, 
but as previously stated, the generalizability of clamps 
is limited. 
Both the OGIS and tests based on fasting 
insulin levels have more clinical applicability for 
assessing insulin resistance compared to the 
hyperinsulinemic-euglycemic clamp test. However, 
insulin resistance testing has never translated to 
improvements in disease risk calculations. The WHO 
definition for insulin resistance means that one in four 
people would be diagnosed with insulin resistance; a 
figure that may be unrelated to their actual health 
risks.60  Analysis from the Women’s Health Initiative 
Biomarkers study showed that although HOMA-IR 
had a positive association with cardiovascular risk, this 
was became non-significant after adjusting for other 
risk factors such as HDL cholesterol.61 There is an 
argument that HOMA-IR should be used in 
combination with HOMA-%B for assessing insulin 
resistance.52 
Emerging research now suggests that insulin 
response patterns following an oral glucose load may 
determine hyperinsulinemic status. Kraft7,10 
demonstrated the variability of insulin response to a 
100 g glucose load over 3-5 hours, especially with 
respect to timing and magnitude of the insulin peak 
and rate of response decline. Five main insulin 
response patterns are clearly identifiable, with pattern I 
being considered normal insulin tolerance.  From this 
research Kraft concluded that the most accurate 
means of assessing hyperinsulinemia was a 3-hour oral 
glucose tolerance test with insulin levels assessed at 
baseline, 30, 60, 120, and, at minimum, 180 minutes 
but 240 and 300 minute insulin levels could also be 
considered. This study was cross-sectional and there 
are no long-term outcomes. 
Hayashi and colleagues62 have shown that the 
insulinemic pattern produced from sampling every 30 
minutes during a 2-hour OGTT can predict the 
development of type 2 diabetes.  An insulin peak 
delayed beyond 60 minutes being associated with 
poorer health is common to both Kraft and Hayashi 
patterns.  Further research is required to understand 
how to apply these patterns to clinical practice. 
Collectively these studies show that there is a 
paucity of research for diagnosing hyperinsulinemia. 
Most studies focus on insulin resistance testing, but it 
remains unknown whether insulin resistance correlates 
with insulin secretion. 
 
Concluding remarks 
This review clearly demonstrates that not only 
is hyperinsulinemia involved with the etiology of all of 
the symptoms of metabolic syndrome, it is also 
implicated in many other conditions; some of which 
have previously been considered to be idiopathic, such 
as tinnitus. This raises many questions with both 
clinical and research implications.  Firstly, what is the 
prevalence of hyperinsulinemia? Given its association 
with metabolic syndrome and fatty liver disease, this 
warrants investigation. Could early detection and 
careful management of hyperinsulinemia decrease the 
need for medical interventions later in life?  Would 
managing hyperinsulinemia improve to both quantity 
and quality of life?  Yet there are currently too many 
questions regarding diagnosis. A reliable and 
repeatable result when sampling insulin is still a 
challenging task.  There is no agreed upon reference 
range, and there are only associations between 
quantiles and ongoing disease risk.  Insulin response 
patterning may answer some of these questions, but 
patterning requires more resources than a fasting level. 
Given the global concerns about the ‘epidemic’ of 
metabolic diseases, this research needs to be urgently 
addressed. 
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